Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1529-1538

  MacLeod, David L ^a   Velayudhan, Jyoti ^a   Kenney, Thomas F ^a   Therrien, Joseph H ^a   Sutherland, Jennifer L ^a   Barker, Lynn M ^a   Baker, William R ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CARBOHYDRATE; FOSFOMYCIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BIOSYNTHESIS; CELL WALL; DOSE RESPONSE; DRUG TRANSPORT; DRUG UPTAKE; GENE MUTATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

BACTERIAL PROTEINS; BIOLOGICAL TRANSPORT, ACTIVE; CARRIER PROTEINS; DRUG SYNERGISM; FOSFOMYCIN; MICROBIAL SENSITIVITY TESTS; MUCINS; MUTATION RATE; PROTEIN BIOSYNTHESIS; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 84857186407     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05958-11     Document Type: Article

References (64)

1. Alper MD, Ames BN. 1978. Transport of antibiotics and metabolite analogs by systems under cyclic-AMP control: positive selection of Salmonella typhimurium cya and crp mutants. J. Bacteriol. 133:149-157. (Pubitemid 8259435)
2. Artman M, Werthamer S. 1974. Use of streptomycin and cyclic adenosine 5″-monophosphate in the isolation of mutants deficient in CAP protein. J. Bacteriol. 120:542-544.
3. Baum EZ, et al. 2001. Identification and characterization of new inhibitors of the Escherichia coli murA enzyme. Antimicrob. Agents Chemother. 45:3182-3188. (Pubitemid 32988847)
4. Bjarnsholt T, Jensen PO, Fiandaca MJ. 2009. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 44:547-558.
5. Borriello G, et al. 2006. Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms. Antimicrob. Agents Chemother. 50:382-384. (Pubitemid 43042953)
6. Bryan LE, Kwan S. 1981. Aminoglycoside-resistant mutants of Pseudomonas aeruginosa deficient in cytochrome d, nitrate reductase, and aerobic transport. Antimicrob. Agents Chemother. 19:958-964. (Pubitemid 11035879)
7. Bucki R, Sostarecz AG, Byfield FJ. 2007. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. J. Antimicrob. Chemother. 60:535-545. (Pubitemid 47299867)
8. Castaneda-Garcia A, et al. 2009. The glycerol-3-phosphate permease glpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J. Bacteriol. 191:6968-6974.
9. Cordaro JC, et al. 1976. Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of Salmonella typhimurium. J. Bacteriol. 128:785-793.
10. Davis SS, et al. 1985. A new mucotropic agent - in vitro and in vivo evaluation of 2-alpha-thenoylthiopropionylglycine (bronchoplus). Eur. J. Respir. Dis. 67:94-102. (Pubitemid 15228533)
11. Driffield K, et al. 2008. Increased mutability of Pseudomonas aeruginosa in biofilms. J. Antimicrob. Chemother. 61:1053-1056. (Pubitemid 351524449)
12. Eagon RG, Phibbs, PV, Jr. 1971. Kinetics of transport of glucose, fructose, and mannitol by Pseudomonas aeruginosa. Can. J. Biochem. 49:1031-1041.
13. Feliziani S, et al. 2010. Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections. PLoS One 5:1-12.
14. Geller DE, Pitlick WH, Nardella PA. 2002. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122:219-226. (Pubitemid 34754166)
15. Glamkowski EJ, et al. 1970. A new synthesis of the antibiotic phosphonomycin. J. Org. Chem. 35:3510-3512.
16. Henke MO, et al. 2007. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am. J. Respir. Crit. Care. Med. 175:816-821. (Pubitemid 46631793)
17. Huh K, et al. 1994. Structures and biological activities of tobramycinticarcillin adducts. J. Pharm. Sci. 83:763-767. (Pubitemid 24233747)
18. Hunt BE, et al. 1995. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob. Agents Chemother. 39:34-39.
19. Jacobs MA, et al. 2003. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 100:14339-14344. (Pubitemid 37499238)
20. Johnson DA, et al. 2008. High-throughput phenotypic characterization of Pseudomonas aeruginosa membrane transport genes. PLoS Genet. 4:1-11.
21. Kahan FM, et al. 1974. The mechanism of action of fosfomycin (phosphonomycin). Ann. N. Y. Acad. Sci. 235:364-386.
22. Kay WW, Gronlund AF. 1969. Amino acid transport in Pseudomonas aeruginosa. J. Bacteriol. 97:273-281.
23. Kirkham S, et al. 2002. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem. J. 361:537-546. (Pubitemid 34177823)
24. Kirkham S, et al. 2008. MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 178:1033-1039.
25. Komatsuzawa H, et al. 2004. The gate controlling cell wall synthesis in Staphylococcus aureus. Mol. Microbiol. 53:1221-1231. (Pubitemid 39120441)
26. Landry RM, An D, Hupp JT. 2006. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance. Mol. Microbiol. 59:142-151.
27. Li W, Lu CD. 2007. Regulation of carbon and nitrogen utilization by CbrAB and NtrBC two-component systems in Pseudomonas aeruginosa. J. Bacteriol. 189:5413-5420. (Pubitemid 47206386)
28. MacLeod DL, et al. 2009. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J. Antimicrob. Chemother. 64:829-836.
29. Martinez JL, Baquero F. 2000. Mutation frequencies and antibiotic resistance. Antimicrob. Agents Chemother. 44:1771-1777. (Pubitemid 30422923)
30. Mendelman PM, et al. 1985. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 132:761-765. (Pubitemid 16247735)
31. Mirakhur A, et al. 2003. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J. Cyst. Fibros. 2:19-24. (Pubitemid 36857405)
32. Mueller M, de la Pena A, Derendorf H. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 48:369-377. (Pubitemid 38141689)
33. Mueller M, de la Pena A, Derendorf H. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:1441-1453. (Pubitemid 38544345)
34. Mulcahy LR, et al. 2010. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J. Bacteriol. 192:6191-6199.
35. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 6th ed. NCCLS document M7-A6. NCCLS, Wayne, PA.
36. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial susceptibility testing; approved standard, 14th ed. NCCLS document M100-S13. NCCLS, Wayne, PA.
37. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved standard. NCCLS document M26-A. NCCLS, Wayne, PA.
38. Nilsson AI, et al. 2003. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. 47:2850-2858. (Pubitemid 37040258)
39. Nishijyo T, Haas D, Itoh Y. 2001. The CbrA-CbrB two-component regulatory system controls the utilization of multiple carbon and nitrogen sources in Pseudomonas aeruginosa. Mol. Microbiol. 40:917-931. (Pubitemid 32523189)
40. Phibbs PV, Jr, Eagon RG. 1970. Transport and phosphorylation of glucose, fructose, and mannitol by Pseudomonas aeruginosa. Arch. Biochem. Biophys. 138:470-482.
41. Phillips JE, et al. 2006. An enzyme-linked immunosorbent assay (ELISA) for the determination of mucin levels in bronchoalveolar lavage fluid. J. Pharmacol. Toxicol. Methods 53:160-167.
42. Purdy Drew KR, et al. 2009. Cationic amphiphiles increase activity of aminoglycoside antibiotic tobramycin in the presence of airway polyelectrolytes. J. Am. Chem. Soc. 131:486-493.
43. Ramphal R, et al. 1988. The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. J. Antimicrob. Chemother. 22:483-490. (Pubitemid 18264816)
44. Ramsey BW, et al. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 340:23-30. (Pubitemid 29024680)
45. Rodriguez A, Vicente MV, Olay T. 1985. Experimental endocarditis and fosfomycin. Drugs Exp. Clin. Res. 11:55-62. (Pubitemid 15130990)
46. Rodriguez A, Vicente MV, Olay T. 1987. Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 31:1444-1445. (Pubitemid 17148322)
47. Rose MC, Voynow JA. 2006. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol. Rev. 86:245-278.
48. Saggers BA, Lawson D. 1966. Some observations on the penetration of antibiotics through mucus in vitro. J. Clin. Pathol. 19:313-317.
49. Saiman L, et al. 2002. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 46:1105-1107. (Pubitemid 34260359)
50. Sarubbi E, et al. 2004. Mode of action of the microbial metabolite GE23077, a novel potent and selective inhibitor of bacterial RNA polymerase. Eur. J. Biochem. 271:3146-3154. (Pubitemid 38998684)
51. Schweizer HP, Po C. 1996. Regulation of glycerol metabolism in Pseudomonas aeruginosa: characterization of the glpR repressor gene. J. Bacteriol. 178:5215-5221. (Pubitemid 26293081)
52. Silo-Suh L, et al. 2005. Adaptations of Pseudomonas aeruginosa to the cystic fibrosis lung environment can include deregulation of zwf, encoding glucose-6-phosphate dehydrogenase. Antimicrob. Agents Chemother. 187:7561-7568. (Pubitemid 41587694)
53. Sriramulu DD, et al. 2005. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J. Med. Microbiol. 54:667-676. (Pubitemid 40885151)
54. Stover CK, et al. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959-964.
55. Taber HW, Mueller JP, Miller PF. 1987. Bacterial uptake of aminoglycoside antibiotics. Microbiol. Rev. 51:439-457. (Pubitemid 18019282)
56. Tamber S, Hancock RE. 2006. Involvement of two related porins, OprD and OpdP, in the uptake of arginine by Pseudomonas aeruginosa. FEMS Microbiol. Lett. 260:23-29. (Pubitemid 43879760)
57. Tamber S, Ochs MM, Hancock REW. 2006. Role of the novel OprD family of porins in nutrient uptake in Pseudomonas aeruginosa. J. Bacteriol. 188:45-54.
58. Tsay SS, Brown KK, Gaudy ET. 1971. Transport of glycerol by Pseudomonas aeruginosa. J. Bacteriol. 108:82-88.
59. Tsuruoka T, Miyata A, Yamada Y. 1978. Two kinds of mutants defective in multiple carbohydrate utilization isolated from in vitro fosfomycin-resistant strains of Escherichia coli K-12. J. Antibiot. 31:192-201. (Pubitemid 8326008)
60. Vakulenko SB, Mobashery S. 2003. Versatility of aminoglycosides and prospects for their future. Clin. Microbiol. Rev. 16:430-450. (Pubitemid 36871315)
61. Valcke Y, Pauwels R, Van der Straeten M. 1990. Pharmacokinetics of antibiotics in the lungs. Eur. Respir. J. 3:715-722. (Pubitemid 20228711)
62. Viswanathan H, et al. 2006. MUC5B secretion is up-regulated in sinusitis compared with controls. Am. J. Rhinol. 20:554-557. (Pubitemid 44575725)
63. Williams SG, Greenwood JA, Jones CW. 1994. The effect of nutrient limitation on glycerol uptake and metabolism in continuous cultures of Pseudomonas aeruginosa. Microbiology 140:2961-2969. (Pubitemid 24359524)
64. Wylie JL, Worobec EA. 1995. The OprB porin plays a central role in carbohydrate uptake in Pseudomonas aeruginosa. J. Bacteriol. 177:3021-3026.